2种长效胰岛素类似物的研究进展 |
| |
引用本文: | 蒋振东 肖拥军 曹春来 等. 2种长效胰岛素类似物的研究进展[J]. 中国现代药物应用, 2014, 0(7): 239-240 |
| |
作者姓名: | 蒋振东 肖拥军 曹春来 等 |
| |
作者单位: | [1]遵义医学院珠海校区,珠海519041 [2]珠海联邦制药有限公司,珠海519041 |
| |
基金项目: | 贵州省免疫学研究生教育创新基地重点培育项目; |
| |
摘 要: | 胰岛素(insulin, INS)首次用于治疗糖尿病以来,随着对糖尿病病理和生理以及发病机制的深入研究,胰岛素得到了许多糖尿病患者的认可。随着重组DNA技术的发展,出现了一批新的长效胰岛素类似物:地特胰岛素(detemir)和德谷胰岛素(degludec)。它们在注射后均可以模拟人胰岛素的分泌方式,持续少量的释放,使餐前和餐后以及夜间的血糖保持稳定;但是随着各方面的深入研究,它们在分子结构、作用机制、生产工艺以及临床应用方面存在着许多不同之处。
|
关 键 词: | 糖尿病 地特胰岛素 德谷胰岛素 |
Research progress of 2 kinds of long-acting insulin analogue |
| |
Abstract: | With the research of the pathophysiology and pathogenesis of diabetes, insulin (INS) had been widely used in the treatment of diabetes. And a number of new long-acting insulin analogues appeared with the development of recombination DNA technology, which could simulate normal basal secretion of insulin. Therefore, the blood sugar level could be kept stable between the intervals of meals or during the night. Insulin detemir and insulin degludec were two novel long-acting insulin analogues in the treatment of diabetes. This review presents the differences between Insulin detemir and insulin degludec in molecular structure, long-term mechanism of action, production process and clinical application. |
| |
Keywords: | Diabetes mellitus Detemir Degludec |
本文献已被 CNKI 维普 等数据库收录! |
|